Camlin Fine Sciences Limited
All news and filings related to Camlin Fine Sciences Limited.
View all news & filings- Medium impact
Camlin Fine Sciences Appoints Atul Pradhan as Additional Non-Executive Independent Director
Camlin Fine Sciences appointed Mr. Atul Pradhan as Additional Non-Executive Independent Director, effective September 11, 2026, for a five-year term. The appointment requires shareholder approval via postal ballot. Mr. Pradhan has extensive experience from KPMG India and Transfolign Consulting.
Read the summary - Medium impact
Camlin Fine Sciences Q1 FY27 Call Transcript Released
Camlin Fine Sciences released its Q1 FY27 earnings call transcript. Revenue increased 28% YoY to INR5,199 million, but margins were impacted by raw material costs. The company expects full-year revenue of INR2,000-2,400 crore and EBITDA margins of 10-12%. They anticipate returning to double-digit EBITDA by Q3 FY27.
Read the summary - Medium impact
Camlin Fine Sciences Q1FY27 Results: Net Loss Widens to ₹317 Crore
Camlin Fine Sciences reported Q1FY27 results with standalone net loss of ₹317.06 million and consolidated net loss of ₹99.61 million. Total income from operations was ₹2,224.86 million (standalone) and ₹5,198.79 million (consolidated). EPS stood at ₹(0.64) standalone and ₹(0.53) consolidated.
Read the summary - Low impact
Camlin Fine Sciences Q1 FY27 Earnings Call Recording Available
Audio recording of Camlin Fine Sciences' Q1 FY27 earnings call, held on August 11, 2026, is available online. The call covered unaudited consolidated and standalone financial results for the quarter ended June 30, 2026. Management confirmed discussions were based on public information.
Read the summary - Medium impact
Camlin Fine Sciences Q1FY27 Revenue Up 27.5% YoY to ₹5,199 Million
Camlin Fine Sciences reported Q1FY27 consolidated revenue of ₹5,199 million, up 27.5% YoY. EBITDA stood at ₹176 million. Specialty Ingredients revenue grew 41% YoY, Blends by 35%, and Aroma by 37%. The company faces challenges from higher raw material and logistics costs but expects continued growth.
Read the summary - Medium impact
Camlin Fine Sciences Q1 FY27 Results: Consolidated Loss Narrows to ₹329.66 Million
Camlin Fine Sciences reported consolidated revenue of ₹5,198.79 million for Q1 FY27. The consolidated net loss narrowed to ₹317.06 million. Standalone revenue was ₹2,224.86 million with a net loss of ₹123.12 million for the quarter ended June 30, 2026. The Board approved these results on August 11, 2026.
Read the summary - Low impact
Camlin Fine Sciences Ltd. Holds 33rd AGM, All Resolutions Passed
Camlin Fine Sciences Limited held its 33rd AGM on August 11, 2026. All resolutions, including financial statement adoption and director re-appointments, were passed with shareholder majority via e-voting. E-voting occurred from August 8-10, 2026.
Read the summary - Low impact
Camlin Fine Sciences to hold Q1 FY27 Earnings Call on Aug 11, 2026
Camlin Fine Sciences will host its Q1 FY27 Earnings Call on Tuesday, August 11, 2026, at 5:00 PM IST. Senior management will discuss un-audited financial results for the quarter ended June 30, 2026. No UPSI will be shared.
Read the summary - Low impact
Camlin Fine Sciences Announces 33rd AGM on August 11, 2026; E-voting from August 8-10
Camlin Fine Sciences will hold its 33rd AGM on August 11, 2026, via VC/OAVM. Remote e-voting is open from August 8-10, 2026. The cut-off date for voting eligibility is August 5, 2026.
Read the summary - Low impact
Camlin Fine Sciences Announces 33rd AGM on Aug 11, 2026, Releases FY26 Annual Report
Camlin Fine Sciences will hold its 33rd AGM on August 11, 2026. The company has released its Annual Report for FY 2025-26. Shareholders are urged to update KYC details for physical securities to ensure timely payments.
Read the summary - Low impact
Camlin Fine Sciences to hold 33rd AGM on Aug 11, 2026, to adopt FY26 financials
Camlin Fine Sciences will hold its 33rd AGM on August 11, 2026, via VC/OAVM. The meeting will adopt audited financial statements for FY 2025-26 and re-appoint directors Mr. Harsha Raghavan and Mr. Jens Van Nieuwenborgh. Remote e-voting is open from August 8-10, 2026.
Read the summary - Low impact
Camlin Fine Sciences Ltd. Announces 33rd AGM on August 11, 2026
Camlin Fine Sciences Limited will hold its 33rd Annual General Meeting on August 11, 2026, at 10:00 AM IST via Video Conferencing. The AGM notice and Annual Report 2025-26 will be distributed electronically to registered members.
Read the summary - Medium impact
Camlin Fine Sciences Completes Vinpai Acquisition After Tender Offer Closes
Camlin Fine Sciences (CFSL) announced the closing of its tender offer for Vinpai shares on July 6, 2026. CFSL now holds 95.41% of Vinpai's share capital and will not implement a squeeze-out procedure.
Read the summary - Low impact
Camlin Fine Sciences Files Certificate Under SEBI (Depositories and Participants) Regulations, 2018
Camlin Fine Sciences Limited submitted a SEBI compliance certificate for Q1 FY27, received from its registrar MUFG Intime India Private Limited. The certificate confirms processing of dematerialised securities for the quarter ended June 30, 2026.
Read the summary - Low impact
Camlin Fine Sciences: Anvarhusen Bilakhiya Resigns as VP - Principal Scientist (R&D)
Mr. Anvarhusen Bilakhiya, Vice President - Principal Scientist (R&D) at Camlin Fine Sciences, has resigned due to personal commitments. His resignation was effective July 7, 2026. The company made the disclosure as per SEBI Listing Regulations.
Read the summary - Low impact
Camlin Fine Sciences Promoter Group Declares No New Share Encumbrance
Ashish Dandekar, for Camlin Fine Sciences' Promoter Group, declared no new encumbrance on company shares as of April 10, 2026. This declaration covers the financial year ending March 31, 2026.
Read the summary - Low impact
Camlin Fine Sciences Holds Investor Meet on July 1, 2026
Camlin Fine Sciences Limited held a group meeting with investors and analysts on July 1, 2026, in Mumbai. Discussions were based on publicly available information, with no unpublished price sensitive information being shared. This update follows a prior disclosure on June 28, 2026.
Read the summary - Low impact
Camlin Fine Sciences to Engage with Investors/Analysts on July 1, 2026
Camlin Fine Sciences will hold a group meeting with investors and analysts on July 1, 2026, in Mumbai. Discussions will be limited to publicly available information.
Read the summary - Medium impact
Camlin Fine Sciences receives French authority clearance for Vinpai tender offer
Camlin Fine Sciences received French authority clearance for its mandatory tender offer on Vinpai shares at EUR 3.60 per share. CFSL previously acquired a majority stake and now holds 83.82% of Vinpai's share capital.
Read the summary - Medium impact
Camlin Fine Sciences Q4 FY26 Earnings Call Transcript Released
Camlin Fine Sciences released its Q4 FY26 earnings call transcript. Revenue was impacted by global conflicts and shipping delays, reaching ₹424 crore for the quarter and ₹1,723 crore for the year. The company reported a ₹100 crore gain from CFS Europe liquidation and expects FY27 revenue of ₹2,200-2,400 crore with 12-14% EBITDA margins. Debt stands at ₹670 crore.
Read the summary - Medium impact
Camlin Fine Sciences Q4FY26 Results: Net Loss of ₹564.95 Lakh
Camlin Fine Sciences reported a standalone net loss of ₹564.95 lakh for Q4FY26. Total income from operations was ₹18,351.65 lakh. Consolidated net profit was ₹8,627.73 lakh with total income of ₹1,72,330.81 lakh for the year.
Read the summary - Low impact
Camlin Fine Sciences Releases Audio Recording of Q4 FY26 Results Conference Call
Camlin Fine Sciences released the audio recording of its Q4 FY26 results conference call held on May 26, 2026. The call covered audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. Management including CMD Mr. Ashish Dandekar participated.
Read the summary - Medium impact
Camlin Fine Sciences Approves Audited FY26 Results; Appoints New CFO
Camlin Fine Sciences approved audited consolidated and standalone financial results for the year and quarter ended March 31, 2026. The 33rd AGM is scheduled for August 11, 2026. Mr. Pankaj Pandey will join as CFO on August 18, 2026, with Mr. Santosh Parab re-designated.
Read the summary - Medium impact
Camlin Fine Sciences Releases Investor Presentation for Q4 & FY26 Results
Camlin Fine Sciences released its investor presentation for Q4 & FY26 results. Revenue for Q4 FY26 was ₹4,248 million and ₹17,233 million for FY26. Blends business grew 17% annually, with Vinpai contributing ₹165 million. EBITDA was ₹212 million with a 5.0% margin. Improved Vanillin realisations and volumes are expected.
Read the summary - Medium impact
Camlin Fine Sciences Board Approves FY26 Audited Results, Appoints New CFO
Camlin Fine Sciences reported audited financial results for FY26. The company appointed Mr. Pankaj Pandey as CFO effective August 18, 2026. The 33rd AGM is scheduled for August 11, 2026. Consolidated loss after tax for FY26 was ₹3,296.62 lakh.
Read the summary - Medium impact
Camlin Fine Sciences Diphenol Plant Shut Down Due to Geopolitical Issues; Fire Incident Reported
Camlin Fine Sciences is shutting down its Diphenol Plant from May 24, 2026, due to raw material constraints and geopolitical issues. A fire incident on May 23, 2026, caused an estimated loss of ₹2 crore, covered by insurance. The company expects to restart Ethyl Vanillin production within 48 hours, with no anticipated impact on downstream sales.
Read the summary - Medium impact
Camlin Fine Sciences Diphenol Plant Shut Down Due to Geopolitical Issues; Fire Incident Reported
Camlin Fine Sciences is shutting its Diphenol Plant due to raw material constraints. A fire incident on May 23, 2026, caused an estimated loss of ₹2 crore, covered by insurance. Ethyl Vanillin production is expected to restart within 48 hours. The company does not foresee a material impact on overall operations.
Read the summary - Low impact
Camlin Fine Sciences: Monitoring Agency Report for Rights Issue Funds for Q4FY26
Camlin Fine Sciences submitted its final Monitoring Agency Report for the Rights Issue for the quarter ended March 31, 2026. The company confirmed no deviation in fund utilization. Total utilized funds were ₹22,468.39 Lakhs, primarily for debt repayment and general corporate purposes.
Read the summary - Medium impact
Camlin Fine Sciences shareholders approve capital increase via postal ballot
Camlin Fine Sciences Limited shareholders approved the increase in Authorized Share Capital via postal ballot on May 7, 2026. The resolution passed with 99.9899% of votes in favour. The voting period concluded on May 7, 2026.
Read the summary - Low impact
Camlin Fine Sciences Promoter Confirms No New Share Encumbrances
Infinity Direct Capital, a promoter of Camlin Fine Sciences, declared no new share encumbrances for FY26 under SEBI Takeover Regulations. All prior encumbrances were previously disclosed.
Read the summary - Low impact
Camlin Fine Sciences: Infinity Portfolio Holdings Declares No New Share Encumbrances
Infinity Portfolio Holdings, a promoter of Camlin Fine Sciences, declared no new share encumbrances for the financial year ended March 31, 2026. This is a routine disclosure under SEBI Takeover Regulations, confirming no additional pledges beyond previously disclosed ones.
Read the summary - Low impact
Camlin Fine Sciences: Promoter Infinity Holdings Declares No New Share Encumbrance
Infinity Holdings, promoter of Camlin Fine Sciences, declared no new share encumbrances. This filing adheres to SEBI (Takeover) Regulations, 2011, confirming no additional pledges beyond disclosures for FY26.
Read the summary - Low impact
Camlin Fine Sciences Promoter Declares No New Encumbrances on Shares
Infinity Direct Holdings, promoter of Camlin Fine Sciences, declares no new encumbrances on shares. This is in accordance with SEBI Takeover Regulations for the financial year ending March 31, 2026. The disclosure confirms no additional pledges beyond previously reported ones.
Read the summary - Low impact
Camlin Fine Sciences Promoter Anfima NV Declares No New Share Encumbrance
Anfima NV, promoter of Camlin Fine Sciences, declared no new share encumbrances. This complies with SEBI Takeover Regulations. All existing encumbrances were previously disclosed for the financial year ending March 31, 2026.
Read the summary - Medium impact
Camlin Fine Sciences Receives ₹5.47 Crore Income Tax Demand Notice for AY24
Camlin Fine Sciences received an Income Tax demand notice for AY24 for ₹5.47 crore due to an Arm's Length Price adjustment. The company believes there is no financial or operational impact and plans to appeal the order. The notice was received on April 10, 2026.
Read the summary - Low impact
Camlin Fine Sciences Announces Postal Ballot for Share Capital Increase
Camlin Fine Sciences is conducting a postal ballot for members to approve an increase in authorized share capital and amend its Memorandum of Association. E-voting is open from April 8 to May 7, 2026. Results are expected by May 9, 2026.
Read the summary - Low impact
Camlin Fine Sciences Files SEBI Reg 74(5) Certificate for Q4FY26
Camlin Fine Sciences Limited submitted a certificate under SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended March 31, 2026. The filing confirms the processing of dematerialised securities by the Registrar and Share Transfer Agent, MUFG Intime India Private Limited.
Read the summary - Low impact
Camlin Fine Sciences seeks shareholder nod to increase authorized share capital
Camlin Fine Sciences is seeking shareholder approval to increase its authorized share capital from ₹21.50 crore to ₹25 crore. This aims to facilitate future fundraising via Rights Issue, QIP, or other equity issuances. E-voting is scheduled from April 8 to May 7, 2026.
Read the summary - Low impact
Camlin Fine Sciences receives tax demand order of ₹96.66 Lakhs
Camlin Fine Sciences received a tax demand order for ₹96.66 Lakhs, including interest and penalty, for non-payment of RCM tax on foreign currency expenses to subsidiaries between FY19-20 and FY22-23. The company received the order on March 30, 2026, and plans to appeal, stating no material impact.
Read the summary - Low impact
Camlin Fine Sciences: Trading Window Closed for Financial Results
Camlin Fine Sciences Limited will close its trading window from April 1, 2026. This is in anticipation of the declaration of Audited Standalone and Consolidated Financial Results for the quarter and year ended March 31, 2026. The window will reopen 48 hours after the results announcement.
Read the summary - High impact
Camlin Fine Sciences subsidiary CFS Europe S.p.A. enters judicial liquidation proceedings
Camlin Fine Sciences subsidiary, CFS Europe S.p.A., has entered judicial liquidation proceedings as ordered by an Italian court on March 17, 2026. The subsidiary contributed 4.72% to CFS's turnover (₹7,873.81 Lakhs) and 9.73% to its net worth (₹8,512.36 Lakhs) as of March 31, 2025.
Read the summary - Medium impact
Camlin Fine Sciences postpones Vinpai tender offer filing to early May 2026
Camlin Fine Sciences will file the draft tender offer for Vinpai shares by early May 2026, postponing the original deadline due to administrative and financial statement considerations. The company will not proceed with a squeeze-out procedure, aiming to maintain Vinpai's listing for strategic restructuring and European expansion.
Read the summary - Medium impact
Camlin Fine Sciences Receives GST Order Demanding ₹23.54 Crore
Camlin Fine Sciences received a GST order demanding ₹23.54 crore for ineligible ITC and imposing a penalty of the same amount. The company received the order on March 16, 2026, and plans to appeal. No material impact is expected on operations.
Read the summary - Low impact
Camlin Fine Sciences to Hold Investor Group Meeting on March 10, 2026
Camlin Fine Sciences will hold a group meeting with investors and analysts on March 10, 2026, in Mumbai. Discussions will be limited to publicly available information.
Read the summary - Medium impact
Camlin Fine Sciences Q3 FY'26 Earnings Call Transcript Released
Camlin Fine Sciences reported Q3 FY'26 revenue of ₹572 crores. The company plans to leverage tariff changes for higher Vanillin realizations. Blends business grew 11%, aided by Vinpai acquisition. Management projects FY'27 gross margins at 46-47% and EBITDA margins at 12-14%. A fire incident in Brazil and liquidation of European entity were also discussed.
Read the summary - Low impact
Camlin Fine Sciences publishes Q3 FY26 Un-audited Financial Results
Camlin Fine Sciences published its un-audited consolidated and standalone financial results for the quarter and nine months ended December 31, 2025. The results were published in Financial Express and Loksatta on February 14, 2026.
Read the summary - Low impact
Camlin Fine Sciences Concall Recording Available for Q3 FY26 Results
Audio recording of Camlin Fine Sciences' concall on Q3 FY26 results (ended Dec 31, 2025) is available. Management included Ashish Dandekar, Nirmal Momaya, and Santosh Parab. Discussions used public information only.
Read the summary - Low impact
Camlin Fine Sciences: No Deviation in Rights Issue Fund Utilization for Q4 2025
Camlin Fine Sciences' Monitoring Agency Report for Q4 2025 confirms no deviation in Rights Issue fund utilization. Total funds were ₹22,468.87 Lakhs. Key uses include debt repayment and general corporate purposes. Unutilized funds are in FDs. A 9-month delay is noted for General Corporate Purposes.
Read the summary - Medium impact
Camlin Fine Sciences Q3FY26 Revenue Up 6.1% to ₹4,572 Crore, Vinpai Acquisition Contributes
Camlin Fine Sciences reported Q3FY26 revenue of ₹457.2 Crore, up 6.1% YoY. Nine-month revenue reached ₹1,340.6 Crore, up 9%. EBITDA was ₹30.7 Crore with a 6.7% margin. The company acquired a majority stake in Vinpai, contributing ₹12.9 Crore revenue in Q3FY26. Outlook remains positive for Vanillin and Blends businesses.
Read the summary - Medium impact
Camlin Fine Sciences Board Approves Q3FY26 Unaudited Financial Results
Camlin Fine Sciences' Board approved Q3FY26 un-audited standalone and consolidated financial results on Feb 13, 2026. A fire occurred at a subsidiary's blending unit in Brazil on Feb 7, 2026; financial impact is undetermined. Operations are suspended at the affected unit.
Read the summary
Model portfolios
Filings are the raw material. These are what SEBI-registered experts build from them.
- Stocks
Udaan
Fast-growing, less-covered companies still early in their runway.
Aggressive29 holdings5+ yearsView portfolio - Stocks
Bharat Rising
Built around India's own shifts: capex, household savings, energy and consumption.
Moderate-Aggressive25 holdings3+ yearsView portfolio - Stocks
All-Terrain
One equity portfolio instead of three: large, mid and small cap in a single book.
Moderate-Aggressive34 holdings3+ yearsView portfolio - Stocks
Core Compounders
Companies that have already been through a downturn and came out still growing.
Moderate20 holdings3+ yearsView portfolio